RxDoctor Payments Data

Steven Morrison, MD

Family Medicine · Southlake, TXNPI 1821002296

Payments from drug & device makers

$2,459in general payments, 2019–2025

Across 115 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$693
  • GSK$381
  • Boehringer Ingelheim$324
  • AbbVie$179
  • Genentech USA, Inc.$105
  • Novo Nordisk$85
  • plus $693 from 22 others

What the payments were for

  • Food & beverage$2,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,459 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$46,822
Medicare patients
165
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$33,309
TrulicityDulaglutide19$20,641
JardianceEmpagliflozin15$20,174
EliquisApixaban15$18,354
Rosuvastatin Calcium195$1,805
Atorvastatin Calcium148$1,326
Ibandronate Sodium37$1,200
Ezetimibe25$938
Levothyroxine Sodium106$746
Metformin Hcl82$687
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril19$546
Fluticasone Propionate11$521
Escitalopram Oxalate39$504
Bupropion XlBupropion Hcl19$466
Albuterol Sulfate HfaAlbuterol Sulfate12$463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$85$33,30934 claims
Lilly USA, LLCTrulicity$11$20,64119 claims
Boehringer IngelheimJardiance$324$20,17415 claims
PfizerEliquis$76$18,35415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Southlake

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →